Processa PharmaceuticalsPCSA +9.64%28 Market Cap is $5.98 Mil as of Jul. 10, 2026. GuruFocus rates PCSA with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,422 Biotechnology companies, Processa Pharmaceuticals ranks worse than 90.37% on this metric.
Processa Pharmaceuticals's quarterly market cap
declined
from Sep. 2025 ($10.15 Mil) to Dec. 2025 ($7.41 Mil) and
declined
from Dec. 2025 ($7.41 Mil) to Mar. 2026 ($6.76 Mil).
Processa Pharmaceuticals's annual market cap
declined
from Dec. 2023 ($8.53 Mil) to Dec. 2024 ($3.27 Mil) but then
increased
from Dec. 2024 ($3.27 Mil) to Dec. 2025 ($7.41 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Processa Pharmaceuticals's Enterprise Value for Today is $0.44 Mil.
Processa Pharmaceuticals (NAS:PCSA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Processa Pharmaceuticals Market Cap Related Terms
Processa Pharmaceuticals Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Processa Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Processa Pharmaceuticals Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Processa Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Processa Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Processa Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Processa Pharmaceuticals (PCSA) has a Market Cap of $5.98 Mil as of Jul. 10, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Processa Pharmaceuticals and its competitors. According to the industry distribution chart, Processa Pharmaceuticals ranks #1285 out of 1422 companies in the Biotechnology industry, placing it in the top 90.4%.
Is Processa Pharmaceuticals' Market Cap too high?
Processa Pharmaceuticals' current Market Cap is $5.98 Mil. The Biotechnology industry median Market Cap is 120.54. Processa Pharmaceuticals' value of $5.98 Mil is 95% below this industry median. Based on the distribution chart, Processa Pharmaceuticals ranks #1285 out of 1422 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Processa Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Processa Pharmaceuticals' Market Cap compare to ELAB and MBIO?
According to the Biotechnology industry distribution chart, Processa Pharmaceuticals ranks #1285 out of 1422 companies for Market Cap. This places Processa Pharmaceuticals in the lower half of its industry. The industry median Market Cap is 120.54. Processa Pharmaceuticals' value of $5.98 Mil is 95% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 120.54, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Processa Pharmaceuticals's current Market Cap of $5.98 Mil is 95% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Processa Pharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 120.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Processa Pharmaceuticals's current Market Cap is $5.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Processa Pharmaceuticals stock overvalued right now?
Processa Pharmaceuticals (PCSA) has a current Market Cap of $5.98 Mil. The current Market Cap is $5.98 Mil and 95% below the Biotechnology industry median of 120.54. Processa Pharmaceuticals' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Processa Pharmaceuticals (PCSA), the current Market Cap is $5.98 Mil as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
28GF Score
Get the complete analysis for PCSA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCSA has been successfully added to your 
